RE:RE:RE:RE:RE:Biotech Take Over - Wall Street JournalDecember 21, 2022 Repost : Abiomed receives FDA accelerated approval for heart pump device.
Today Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial.
Abiomed has a market cap of US$17.1 Billion
https://www.biospace.com/article/releases/fda-approves-impella-ecp-pivotal-heart-pump-and-first-patients-enrolled-in-pivotal-clinical-trial/
....................................................
A market cap of US$17 Billion is significant for a medical device company in the auxilliary heart pump device business when the global heart pump device market size is estimated to be USD$ 5.5 billion by 2026. Up from US$1.6 Billion in 2020.
https://www.marketsandmarkets.com/Market-Reports/heart-pump-device-market-237125725.html
https://www.globenewswire.com/en/news-release/2022/09/08/2512126/0/en/Heart-Pump-Device-Market-Size-and-Upcoming-Technological-Innovations-Will-Boom-in-2022-2028-Analyzed-by-Size-Share-Trends-Key-Players-Future-Growth-Outlook.html
In contrast the global immune checkpoint inhibitors market size was exhibited at US$ 31.4 billion in 2021 and it is expected to hit around US$ 148.1 billion by 2030 with a registered CAGR of 18.81% during the forecast period 2022 to 2030.
https://www.precedenceresearch.com/immune-checkpoint-inhibitors-market
Meanwhile the global oncology markt was valued at US$ 286.04 Billion in 2021 and is expected to reach over US$ 581.25 Billion by 2030.
The breast cancer market size in 2021 was US$57.7 Billion.